Status:
UNKNOWN
Early and Accurate Detection of Prostate Cancer in General Practice
Lead Sponsor:
Aarhus University Hospital
Collaborating Sponsors:
Regional Hospital Holstebro
University of Aarhus
Conditions:
Prostate Cancer
Prostate Neoplasm
Eligibility:
MALE
50-69 years
Phase:
NA
Brief Summary
Prostate cancer (PC) is the most common malignancy (4500 new cases/year) and the second leading cause of cancer-associated mortality (1200 deaths/year) among men in Denmark. PC is generally diagnosed ...
Detailed Description
While early stage PC can be cured by surgery or radiation therapy, advanced PC is incurable and associated with high morbidity and mortality. Early detection is critical to save lives, but many newly ...
Eligibility Criteria
Inclusion
- aged 50-69 years
- no previous pelvic cancer
- no previous prostate biopsy
- no previous elevated PSA results
- informed consent from the participant
Exclusion
- palpable prostatae tumor by digital rectal examination
- previously diagnosed with/or treated for an urogenital cancer disease
- contraindications to 3 T MRI
- known severe renal impairment with estimated glomerular filtration rate \<30 ml / min
Key Trial Info
Start Date :
January 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2021
Estimated Enrollment :
3000 Patients enrolled
Trial Details
Trial ID
NCT03431753
Start Date
January 1 2018
End Date
December 31 2021
Last Update
May 4 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
General Practice
Aarhus, Central Jutland, Denmark, 8200